MS - Timely Progression to Natalizumab for greatest possible Benefit

被引：0
|
作者：
不详
机构：
来源：
FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE | 2013年 / 81卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [21] The Greatest Benefit to Mankindedited by Roy Porter
    L S Illis
    Spinal Cord, 1998, 36 (8) : 597 - 597
  • [22] PML: underdiagnosed in MS patients on natalizumab
    Steiner, Israel
    LANCET NEUROLOGY, 2010, 9 (06): : 564 - 564
  • [23] No Difference in Disability Progression of MS Patients Treated with Extended Interval vs. Standard Interval Natalizumab
    Fallon, Julia
    Kister, Ilya
    Ryerson, Lana Zhovtis
    NEUROLOGY, 2016, 86
  • [24] Natalizumab efficacy on cognitive impairment in MS
    F. Mattioli
    C. Stampatori
    F. Bellomi
    R. Capra
    Neurological Sciences, 2011, 31 : 321 - 323
  • [25] JC linked with natalizumab in MS patients
    不详
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (09) : 1051 - 1051
  • [26] Quantitative risk-benefit analysis of natalizumab
    Thompson, J. P.
    Noyes, K.
    Dorsey, E. R.
    Schwid, S. R.
    Holloway, R. G.
    NEUROLOGY, 2008, 71 (05) : 357 - 364
  • [27] Natalizumab improves neurological function in MS
    Iley Ozerlat
    Nature Reviews Neurology, 2011, 7 (5) : 246 - 246
  • [28] Natalizumab in MS: JC antibody index
    Fung, W.
    Robertson, N. P.
    JOURNAL OF NEUROLOGY, 2015, 262 (02) : 492 - 494
  • [29] Malignant melanoma in natalizumab recipients with MS
    Reactions Weekly, 2018, 1728 (1) : 10 - 10
  • [30] Natalizumab: a new way for MS treatment
    Sidorenko, T. V.
    Kolyak, E. V.
    Boyko, A. N.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2009, 109 (07) : 122 - 128
12345